Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.
David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
